STAT+

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a thumbs down for an Alzheimer’s drug, Pfizer gene therapy struggles, and more

Biotech Andrew Joseph

STAT Plus: European regulators say Alzheimer’s therapy Leqembi should be rejected

Politics Aaron Pressman — Boston Globe

STAT Plus: Powerful Senate committee demands testimony from CEO of bankrupt Steward hospital chain

D.C. Diagnosis Rachel Cohrs Zhang

STAT Plus: The state pharma’s targeting this election cycle

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: A preview of Neurocrine’s muscarinic drug readout

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a Viking obesity drug, Bausch Health’s bankruptcy denial, and more

Health tech Katie Palmer

STAT Plus: Federal regulation of health data and AI expected to get a boost after HHS revamp

Biotech Elaine Chen

STAT Plus: Viking accelerates development of obesity drug that could rival Wegovy, Zepbound

Exclusive Megan Molteni

STAT Plus: Jiankui He, creator of CRISPR-edited children, relocates to a Chinese medical tourism hub

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a CVS deal with Illinois, a Pfizer hemophilia therapy, and more

Biotech Adam Feuerstein

STAT Plus: Sage suffers pipeline setback with failure of drug to treat essential tremor

Pharma Jason Mast

STAT Plus: Pfizer gene therapy reduced hemophilia bleeds, but questions remain

Health tech Timmy Broderick

STAT Plus: Robotic aid helped improve balance, gait in children with cerebral palsy

Opinions+ Priya Baraniak

STAT Plus: Cell donors are essential for new therapies. They need to be taken care of

Exclusive Ed Silverman

STAT Plus: CVS and its PBM agree to pay $45 million to Illinois for failing to pass drug rebates

Pharmalot Ed Silverman

STAT Plus: U.S. Patent Office software mistakes extend patent life for drugs and need to be fixed, researchers say

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about PBM practices, DOJ tussling with Regeneron, and more

Biotech Allison DeAngelis

STAT Plus: Biotech led by J&J veterans launches with $165 million for cancer, autoimmune therapies

Politics Nicholas Florko

STAT Plus: Medical groups are divided over Biden plan to loosen DEA restrictions on marijuana

Pharmalot Ed Silverman

STAT Plus: A pricey Gilead HIV drug could be made for dramatically less than the company charges, researchers say

Health Care Inc. Bob Herman

STAT Plus: Medicare and Medicaid struggles foreshadow a rocky health insurer earnings season

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Express Scripts overcharging postal workers, Gilead’s AIDS drug price, and more

Pharmalot Ed Silverman

STAT Plus: European Commission reaches deal with Vifor for ‘disparaging’ its only rival in iron deficiency market

Pharmalot Bob Herman and Ed Silverman

STAT Plus: Express Scripts overcharged postal workers by $45 million, audit says

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about an FDA rare disease innovation hub, fewer U.S. drug shortages, and more

Politics Olivia Goldhill

STAT Plus: FDA investigators have not spoken with patients and others alleging misconduct in MDMA trials

D.C. Diagnosis Rachel Cohrs Zhang

STAT Plus: Here come Medicare’s first negotiated drug prices

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: Novartis not ready to admit a $3 billion mistake